Inoviq Ltd (DE:EGQ0)
FRANKFURT:EGQ0
EGQ0 Stock Chart & Stats
€0.21
-€0.02(-5.23%)
At close: 4:00 PM EST
€0.21
-€0.02(-5.23%)
Day’s Range― - ―
52-Week Range€0.16 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€29.27M
Enterprise Value€24.43M
Total Cash (Recent Filing)€13.80M
Total Debt (Recent Filing)€270.31K
Price to Earnings (P/E)―
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio reduces refinancing and interest-rate risk, giving management financial flexibility to fund R&D, partnerships or commercial rollouts without immediate debt pressure. Over several months this supports operational stability and strategic optionality while profitability is addressed.
Proprietary Exosome PlatformA specialized exosome-based diagnostics platform creates durable competitive differentiation and potential high barriers to entry due to technical know-how and IP. This platform orientation supports multi-year opportunities in oncology and research markets, enabling licensing and recurring reagent/test revenues if commercial adoption progresses.
Diversified Commercialization ModelA mixed revenue approach—research product sales, diagnostics commercialization and partner/licence deals—reduces single-stream dependency. Structurally, milestone and royalty arrangements can produce non-linear, high-margin cash inflows and help fund operations during technology validation phases if partnerships are secured.
Bears Say
Declining Revenue & Negative MarginsSustained revenue decline and loss-making operations indicate the business has not achieved commercial scale. Over months, this reduces internal funding for product development and commercialization, erodes partner negotiating power, and increases dependency on external capital unless revenue and margin trends reverse.
Weak Cash GenerationPersistent negative operating and free cash flows threaten runway and force choices between dilutive financing, spending cuts, or slower development. For a diagnostics company with multi-stage commercialization needs, weak cash generation is a structural risk to executing partnerships, scaling sales, and maintaining R&D momentum.
Poor Return On EquityA materially negative ROE signals that invested capital is producing losses rather than returns, undermining investor confidence and making non-dilutive funding harder to secure. Over the coming months, this hampers the firm's ability to attract strategic partners or finance growth without significant strategic or operational changes.
Inoviq Ltd News
EGQ0 FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest stock price was €0.16 and its highest was €0.24 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is €29.27M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in DE:EGQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:EGQ0 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €83.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.47%
12-Months-Change
Fundamentals
Return on Equity
-37.14%
Trailing 12-Months
Asset Growth
15.77%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Options Prices
Currently, No data available
---